Latest News

T-DXd Yields PFS Across Mutation Subtypes for HR+, HER2-low Breast Cancer
T-DXd Yields PFS Across Mutation Subtypes for HR+, HER2-low Breast Cancer

May 31st 2025

In the phase 3 DESTINY-Breast06 trial, the overall biomarker-evaluable population’s confirmed ORR was 59.4% with T-DXd vs 33.9% with chemotherapy.

PROs Favor Imlunestrant With/Without Abemaciclib in ER+, HER2– Breast Cancer
PROs Favor Imlunestrant With/Without Abemaciclib in ER+, HER2– Breast Cancer

May 31st 2025

Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors
Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors

May 31st 2025

Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC
Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC

May 31st 2025

Vepdegestrant Outperforms Fulvestrant in PFS for ESR1-Mutant Advanced Breast Cancer
Vepdegestrant Outperforms Fulvestrant in PFS for ESR1-Mutant Advanced Breast Cancer

May 31st 2025